98%
921
2 minutes
20
Objectives: To derive systematic-review informed, modified Delphi consensus regarding anticoagulation monitoring assays and target levels in pediatric extracorporeal membrane oxygenation (ECMO) for the Pediatric ECMO Anticoagulation CollaborativE.
Data Sources: A structured literature search was performed using PubMed, EMBASE, and Cochrane Library (CENTRAL) databases from January 1988 to May 2021.
Study Selection: Anticoagulation monitoring of pediatric patients on ECMO.
Data Extraction: Two authors reviewed all citations independently, with a third independent reviewer resolving any conflicts. Evidence tables were constructed using a standardized data extraction form.
Data Synthesis: Risk of bias was assessed using the Quality in Prognosis Studies tool or the revised Cochrane risk of bias for randomized trials, as appropriate and the evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation system. Forty-eight experts met over 2 years to develop evidence-based recommendations and, when evidence was lacking, expert-based consensus statements for clinical recommendations focused on anticoagulation monitoring and targets, using a web-based modified Delphi process to build consensus (defined as > 80% agreement). One weak recommendation, two consensus statements, and three good practice statements were developed and, in all, agreement greater than 80% was reached. We also derived some resources for anticoagulation monitoring for ECMO clinician use at the bedside.
Conclusions: There is insufficient evidence to formulate optimal anticoagulation monitoring during pediatric ECMO, but we propose one recommendation, two consensus and three good practice statements. Overall, the available pediatric evidence is poor and significant gaps exist in the literature.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216399 | PMC |
http://dx.doi.org/10.1097/PCC.0000000000003494 | DOI Listing |
Introduction Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not only as a pulmonary condition but as a systemic disorder with significant cardiovascular implications. Acute exacerbations of COPD (AECOPD) further elevate this risk, potentially through a heightened prothrombotic state. This study aimed to evaluate and compare the levels of select prothrombotic biomarkers - fibrinogen, C-reactive protein (CRP), D-dimer, von Willebrand Factor (vWF), homocysteine, lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) - in patients with stable COPD and AECOPD, and to assess their diagnostic and prognostic significance.
View Article and Find Full Text PDFHeart Rhythm O2
August 2025
Hospital Privado del Sur & Hospital Regional Español, Bahía Blanca, Argentina.
Background: Patient characteristics and outcomes of newly diagnosed atrial fibrillation (AF) have been investigated in large registries.
Objective: The study aimed to address the role of non-invasive screening tools in diagnosing AF in the Argentinian clinical practice.
Methods: This was an observational retrospective study.
Heart Rhythm O2
August 2025
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Background: The recurrence of arrhythmia following catheter ablation of macro-reentrant atrial tachycardia (MRAT) in repaired tetralogy of Fallot (rTOF) is poorly understood.
Objective: To better describe the incidence, mechanisms, and predictors of recurrent atrial arrhythmia following MRAT ablation in rTOF.
Methods: Patients with rTOF ≥18 years of age who underwent radiofrequency ablation for MRAT (typical/cavotricuspid isthmus-dependent atrial flutter, incisional/scar-mediated MRAT, upper and lower-loop reentry, or left atrial MRAT) at Duke University Hospital from 1996 to 2023 were identified.
J Enzyme Inhib Med Chem
December 2025
School of Life Sciences, Jinggangshan University, Ji'an, China.
Current antithrombotic therapies face dual constraints of bleeding complications and monitoring requirements. Although natural hirudin provides targeted thrombin inhibition, its clinical adoption is hindered by sourcing limitations. This study developed a recombinant hirudin variant HMg (rHMg) with enhanced anticoagulant activity through genetic engineering and established cost-effective large-scale production methods.
View Article and Find Full Text PDFJ Cardiothorac Vasc Anesth
August 2025
Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany; Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, Bonn, Germany.
Objectives: To determine the incidence and subsequent complications of internal jugular vein (IJV) thrombosis after cannulation performed during cardiopulmonary bypass (CPB) to ensure adequate venous drainage during minimally invasive cardiac surgery.
Design: Single-center observational trial SETTINGS: Intensive care postoperative monitoring of cardiac surgery patients and diagnosis of IJV thrombi at a university tertiary hospital during the 13-month study period from December 1, 2022, to January 11, 2024.
Participants: 44 patients undergoing catheterization of the IJV for total CPB.